Abstract
The rupture or bleeding of a gastrointestinal stromal tumor (GIST) is a life-threatening adverse event that can happen during imatinib therapy, but few such cases have been reported in the medical literature. Here, we report a case of intraperitoneal bleeding from GIST during imatinib therapy. A 75-year-old man was diagnosed with a large GIST with liver metastasis and admitted to our hospital for abdominal pain on the 13th day of imatinib therapy. The pain disappeared after 7 days of hospitalization; however, the patient complained of diffuse abdominal pain 5 days after discharge. He presented with muscular guarding, and abdominal-pelvic CT demonstrated dense ascites. The tentative diagnosis was peritoneal hemorrhage from GIST, and urgent laparotomy was performed. During the laparotomy, we noted hemoperitoneum of approximately 500 ml; we resected a bulky metastatic tumor on the greater omentum and a primary tumor on the jejunum. The patient took imatinib (400 mg daily) from the ninth postoperative day and underwent monthly checkups for 9 months after the surgery. When GIST patients complain of sudden and severe abdominal pain during imatinib therapy, bleeding from GIST should be considered as a possible adverse effect of imatinib.
Similar content being viewed by others
References
Miettinen M, Laseta J. Gastrointestinal stromal tumors (GISTs): definition, occurrence, pathology, differential diagnosis and molecular genetics. Pol J Pathol. 2003;54:3–24.
Demetri GD, Mehren M, Blanke CD, Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med. 2002;347:472–80.
van Oosterom AT, Judson I, Verweij J, Stroobants S, Donato di Paola E, Dimitrijevic S, et al. European Organisation for Research and Treatment of Cancer. Soft Tissue and Bone Sarcoma Group. Lancet. 2001;358:1421–3.
Oku T, Waga E, Sumiyoshi T, Yoshizaki N, Kondo H, Ohira N, et al. A case of primary small intestinal gastrointestinal stromal tumor: an intraperitoneal bleeding from greater omentum metastasis caused by administration of imatinib mesylate. Nippon Shokakibyo Gakkai Zassi (JJSG). 2003;100:863–7. (in Japanese with English abstract).
Hirasaki S, Fujita K, Matsubara M, Kanzaki H, Yamane H, Okuda M, et al. A ruptured large extraluminal ileal gastro-intestinal stromal tumor causing hemoperitoneum. World J Gastroenterol. 2008;14:2928–31.
Cegarra-Navarro MF, Corral de la Calle MA, Girela-Baena E, Garcia-Santos JM, Lloret-Eston F. Ruptured gastro-intestinal stromal tumors: radiologic findings in six cases. Abdom Imaging. 2005;30:535–42.
Demetri GD, Benjamin RS, Blanke CD, Blay JY, Casali P, Choi H, et al. NCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST): update of the NCCN clinical practice guidelines. J Natl Compr Canc Netw 2007;5(suppl 2):S1–S29.
Blanke CD, Rankin C, Demetri GD, Ryan CW, von Mehren M, Benjamin RS, et al. Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol. 2008;26:626–32.
Yokoyama A, Dairaku N, Kusano M, Koshita S, Shimada N, Yamagiwa T, et al. Two cases of primary unresectable and/or recurrent gastrointestinal stromal tumors of small intestine presenting hemoperitoneum caused by administration of imatinib mesylate. Nippon Shokakibyo Gakkai Zassi (JJSG). 2008;105:1619–26. (in Japanese with English abstract).
Bonvalot S, Eldweny H, Le Pechoux C, Vanel D, Terrier P, Cavalcanti A, et al. Impact of surgery on advanced gastrointestinal stromal tumors (GIST) in the imatinib era. Ann Surg Oncol. 2006;13:1596–603.
Heinrich MC, Corless C, Demetri GD, Blanke C, Mehren M, Joensuu H, et al. Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor. J Clin Oncol. 2003;21:4342–9.
Debiec-Rychter M, Sciot R, Le Cesne A, Schlemmer M, Hohenberger P, Oosterom AT, et al. KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumors. Eur J Cancer. 2006;42:1093–103.
Yeh NN, Chen TW, Liu FY, Jan YY, Chen FF. Genetic changes in advanced gastrointestinal stromal tumor (GIST) patients during imatinib mesylate treatment. Langenbecks Arch Surg. 2006;391:615–21.
Cruz RJ Jr, Vincenzi R, Ketzer BM, Cecilio AL, Cepeda LA. Spontaneous intratumoral bleeding and rupture of giant gastric stromal tumor (>30 cm) in a young patient. World J Surg Oncol 2008;6:76.
Burkill GJ, Badran M, Al-Muderis O, Meirion Thomas J, Judson IR, Fisher C, et al. Malignant gastrointestinal stromal tumor: distribution, imaging features, pattern of metastatic spread. Radiology. 2003;226:527–32.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Enomoto, T., Kanda, T., Yajima, K. et al. Urgent surgery for intraperitoneal bleeding from GIST during imatinib therapy. Clin J Gastroenterol 3, 73–77 (2010). https://doi.org/10.1007/s12328-010-0143-3
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12328-010-0143-3